Paper · 2026 · Open access

PHARMACOGENOMICS IN PERSONALIZED MEDICINE: OPTIMIZING DRUG THERAPY FOR IMPROVED CLINICAL OUTCOME

Aswathy U. J.2 Aswathy S. J.1*

Zenodo (CERN European Organization for Nuclear Research) · Published 1 October 2026 · DOI 10.5281/zenodo.23031299

Open full textCite this paper

In brief

“PHARMACOGENOMICS IN PERSONALIZED MEDICINE: OPTIMIZING DRUG THERAPY FOR IMPROVED CLINICAL OUTCOME” is a 2026 paper by Aswathy U. J.2 Aswathy S. J.1*, published in Zenodo (CERN European Organization for Nuclear Research). OpenAlex counts 0 citations as of 21 November 2026. It is open access under a CC BY licence: the full text is free to read at Zenodo (CERN European Organization for Nuclear Research).

Citations
0
Authors
1

Abstract

Pharmacogenomics (PGx) is an emerging discipline that integrates genomic information into clinical decision-making to optimize drug therapy, enhance efficacy, and reduce adverse drug reactions. Variability in drug response among individuals is influenced by genetic polymorphisms in drug-metabolizing enzymes, transporters, and receptors.[1] Recent developments, including clinical guidelines from the Clinical Pharmacogenetics Implementation Consortium (CPIC) and regulatory support from agencies such as the FDA, have accelerated the implementation of pharmacogenomic testing in routine healthcare.[2] Applications of PGx are particularly significant in oncology, cardiology, psychiatry, and rare diseases, where genotype-guided therapy has demonstrated improved therapeutic outcomes and reduced toxicity.[3] Emerging technologies such as next-generation sequencing, artificial intelligence, and multi-omics approaches are expected to further enhance the clinical utility of pharmacogenomics. Differences in drug response among patients often arise due to genetic polymorphisms affecting drug metabolism, transport, and targets. These variations can lead to therapeutic inefficacy or adverse drug reactions (ADRs), posing significant clinical challenges.[4] The integration of pharmacogenomics into personalized medicine enables clinicians to tailor treatments, improving efficacy and minimizing toxicity.[5]

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

J.1*, A. U. J. A. S. (2026). PHARMACOGENOMICS IN PERSONALIZED MEDICINE: OPTIMIZING DRUG THERAPY FOR IMPROVED CLINICAL OUTCOME. Zenodo (CERN European Organization for Nuclear Research). https://doi.org/10.5281/zenodo.23031299

MLA 9

J.1*, Aswathy U. J.2 Aswathy S. “PHARMACOGENOMICS IN PERSONALIZED MEDICINE: OPTIMIZING DRUG THERAPY FOR IMPROVED CLINICAL OUTCOME.” Zenodo (CERN European Organization for Nuclear Research), 2026. https://doi.org/10.5281/zenodo.23031299.

Chicago

J.1*, Aswathy U. J.2 Aswathy S. 2026. “PHARMACOGENOMICS IN PERSONALIZED MEDICINE: OPTIMIZING DRUG THERAPY FOR IMPROVED CLINICAL OUTCOME.” Zenodo (CERN European Organization for Nuclear Research). https://doi.org/10.5281/zenodo.23031299.

Harvard

J.1*, A. U. J. A. S. (2026) ‘PHARMACOGENOMICS IN PERSONALIZED MEDICINE: OPTIMIZING DRUG THERAPY FOR IMPROVED CLINICAL OUTCOME’, Zenodo (CERN European Organization for Nuclear Research). doi:10.5281/zenodo.23031299.

IEEE

A. U. J. A. S. J.1*, “PHARMACOGENOMICS IN PERSONALIZED MEDICINE: OPTIMIZING DRUG THERAPY FOR IMPROVED CLINICAL OUTCOME,” Zenodo (CERN European Organization for Nuclear Research), 2026, doi: 10.5281/zenodo.23031299.

BibTeX

@article{j12026pharmacogenomics,
  title     = {{PHARMACOGENOMICS IN PERSONALIZED MEDICINE: OPTIMIZING DRUG THERAPY FOR IMPROVED CLINICAL OUTCOME}},
  author    = {J.1*, Aswathy U. J.2 Aswathy S.},
  journal   = {Zenodo (CERN European Organization for Nuclear Research)},
  year      = {2026},
  doi       = {10.5281/zenodo.23031299},
  url       = {https://doi.org/10.5281/zenodo.23031299}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism

  • pharmacogenomics
  • personalized medicine
  • drug response variability
  • genetic polymorphism
  • drug-metabolizing enzymes
  • drug transporters
  • adverse drug reactions
  • pharmacogenetic testing

Work with this paper

Most-cited papers in Pharmacology, Toxicology and Pharmaceutics

All highly cited Pharmacology, Toxicology and Pharmaceutics papers

Questions about this paper

How do I cite this paper in APA style?

J.1*, A. U. J. A. S. (2026). PHARMACOGENOMICS IN PERSONALIZED MEDICINE: OPTIMIZING DRUG THERAPY FOR IMPROVED CLINICAL OUTCOME. Zenodo (CERN European Organization for Nuclear Research). https://doi.org/10.5281/zenodo.23031299

How many times has this paper been cited?

0 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Zenodo (CERN European Organization for Nuclear Research): sign in and open the full text from this page.

Who wrote this paper?

Aswathy U. J.2 Aswathy S. J.1*.

What is the DOI of this paper?

10.5281/zenodo.23031299, permanently at https://doi.org/10.5281/zenodo.23031299. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.